Compare Lennar Corporation (LEN) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lennar Corporation vs Tenet Healthcare Corporation — how do they compare? Lennar Corporation trades at $76.43 (market cap $18.44B), while Tenet Healthcare Corporation trades at $263.45 (market cap $20.98B). The key difference: Lennar Corporation and Tenet Healthcare Corporation are close in size by market cap, and Lennar Corporation pays a 2.58% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lennar Corporation for 67 Days and Tenet Healthcare Corporation for 15 Days on average.
| LEN | THC | |
|---|---|---|
Market Cap | $18.44B | $20.98B |
Volume | 6,012,214 | 428,008 |
Sector | Consumer Cyclical | Health |
52-Week High | $133.13 | $280.77 |
52-Week Low | $74.44 | $161.37 |
Typical Hold Time | 67 Days | 15 Days |
Enterprise Value | $22.86B | $32.06B |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lennar (LEN) trades at $76.04, down 0.12% with bearish technical signals and recent earnings misses. The stock shows attractive valuation metrics with P/E of 14.7 and P/B of 0.86, but faces declining profitability with net margin dropping to 4.09% in 2025. Berkshire Hathaway's significant stake accumulation contrasts with Morgan Stanley's sell rating, highlighting divergent views on the housing market recovery timeline.
The investment case balances deep value against cyclical headwinds. While trading below book value and showing institutional confidence from Berkshire, Lennar faces mortgage rate pressures and earnings volatility. The consensus price target of $77.38 suggests limited upside, requiring careful monitoring of housing market conditions and execution on the asset-light strategy.
Tenet Healthcare (THC) trades at $265.42, up 2.15% today, with a bullish technical signal from moving averages and strong support near $257. The company shows robust fundamentals, including a 53.31% ROE and consistent earnings beats, with Q3 2026 results due October 29. Revenue growth is supported by higher revenue per case despite softer surgical volumes, as noted by Zacks on September 24, 2026.
The outlook is positive, with an 81.25% analyst buy rating and a $283.36 consensus price target implying ~7% upside. Risks include sustainability of capital returns amid growth investments and potential volume pressures, but solid cash flow and valuation metrics like a 10.07 P/E suggest room for appreciation if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
